Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Bhide N, Lindenbach D, Surrena MA, Goldenberg AA, Bishop C, Berger SP, Paquette MA.

Psychopharmacology (Berl). 2013 Jun;227(3):533-44. doi: 10.1007/s00213-013-3001-4. Epub 2013 Feb 7.

2.

The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP.

Psychopharmacology (Berl). 2009 Jul;204(4):743-54. doi: 10.1007/s00213-009-1505-8. Epub 2009 Mar 13. Erratum in: Psychopharmacology (Berl). 2009 May;204(1):185-7.

3.

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.

Neuropharmacology. 2015 Jun;93:52-67. doi: 10.1016/j.neuropharm.2015.01.012. Epub 2015 Jan 31.

PMID:
25645393
4.

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.

Pinna A, Ko WK, Costa G, Tronci E, Fidalgo C, Simola N, Li Q, Tabrizi MA, Bezard E, Carta M, Morelli M.

Mov Disord. 2016 Apr;31(4):501-11. doi: 10.1002/mds.26475. Epub 2016 Feb 12.

PMID:
26871939
5.

Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.

Lindenbach D, Dupre KB, Eskow Jaunarajs KL, Ostock CY, Goldenberg AA, Bishop C.

Brain Res. 2013 Nov 6;1537:327-39. doi: 10.1016/j.brainres.2013.09.020. Epub 2013 Sep 21.

6.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
7.

Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.

Bhide N, Lindenbach D, Barnum CJ, George JA, Surrena MA, Bishop C.

J Neurochem. 2015 Jul;134(2):222-32. doi: 10.1111/jnc.13125. Epub 2015 Apr 27.

8.

The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.

Shin E, Lisci C, Tronci E, Fidalgo C, Stancampiano R, Björklund A, Carta M.

Neurobiol Dis. 2014 Feb;62:233-40. doi: 10.1016/j.nbd.2013.09.021. Epub 2013 Oct 14.

PMID:
24135006
9.

Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.

Dupre KB, Cruz AV, McCoy AJ, Delaville C, Gerber CM, Eyring KW, Walters JR.

Neurobiol Dis. 2016 Feb;86:1-15. doi: 10.1016/j.nbd.2015.11.009. Epub 2015 Nov 14.

10.

Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.

Iderberg H, Rylander D, Bimpisidis Z, Cenci MA.

Exp Neurol. 2013 Dec;250:116-24. doi: 10.1016/j.expneurol.2013.09.003. Epub 2013 Sep 10.

PMID:
24029003
11.

The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.

Frau R, Savoia P, Fanni S, Fiorentini C, Fidalgo C, Tronci E, Stancampiano R, Meloni M, Cannas A, Marrosu F, Bortolato M, Devoto P, Missale C, Carta M.

Exp Neurol. 2017 May;291:1-7. doi: 10.1016/j.expneurol.2017.01.012. Epub 2017 Jan 26.

PMID:
28131725
12.

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A.

Exp Neurol. 2015 Sep;271:335-50. doi: 10.1016/j.expneurol.2015.05.021. Epub 2015 May 30.

PMID:
26037043
13.

Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, Zu J, Zhang W, Shen X, Cui G, Hua F.

Exp Neurol. 2015 Sep;271:168-74. doi: 10.1016/j.expneurol.2015.05.007. Epub 2015 May 20.

PMID:
26001615
14.

A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.

Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.

Exp Neurol. 2005 Feb;191(2):243-50.

PMID:
15649479
15.

Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Fidalgo C, Ko WK, Tronci E, Li Q, Stancampiano R, Chuan Q, Bezard E, Carta M.

Neuroscience. 2015 Jul 9;298:389-96. doi: 10.1016/j.neuroscience.2015.04.027. Epub 2015 Apr 20.

PMID:
25907446
16.

Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

Kumar R, Riddle LR, Griffin SA, Chu W, Vangveravong S, Neisewander J, Mach RH, Luedtke RR.

Neuropharmacology. 2009 May-Jun;56(6-7):956-69. doi: 10.1016/j.neuropharm.2009.01.019. Epub 2009 Feb 5.

17.

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.

Bézard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.

Neurosci Res. 2013 Dec;77(4):242-6. doi: 10.1016/j.neures.2013.10.002. Epub 2013 Oct 14.

PMID:
24135129
18.

Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model.

Flores AJ, Bartlett MJ, So LY, Laude ND, Parent KL, Heien ML, Sherman SJ, Falk T.

Neurosci Lett. 2014 Apr 3;564:48-52. doi: 10.1016/j.neulet.2014.02.004. Epub 2014 Feb 11.

19.
20.

Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Gerlach M, Bartoszyk GD, Riederer P, Dean O, van den Buuse M.

J Neural Transm (Vienna). 2011 Dec;118(12):1733-42. doi: 10.1007/s00702-010-0571-8. Epub 2011 Jan 21.

PMID:
21253782

Supplemental Content

Support Center